Chronic graft-versus-host disease (GVHD) is the leading cause of late, nonrelapse mortality
and disability in allogeneic hematopoietic cell transplantation recipients and a major …

In recent years, there has been a tremendous development of biotechnological,
pharmacological, and medical techniques which can be implemented in the functional …

Background Prevention of graft-versus-host disease (GvHD) without malignant relapse is the
overall goal of allogeneic haemopoietic cell transplantation (HCT). We aimed to evaluate …

Graft-vs. host disease (GVHD), both acute and chronic are among the chief non-relapse
complications of allogeneic transplantation which still cause substantial morbidity and …

Graft-versus-host disease (GvHD) was first described in 1959, since then major efforts have
been made in order to understand its physiopathology and animal models have played a …

Oral mucositis (OM) is a debilitating early adverse effect of allogeneic hematopoietic stem
cell transplantation (HSCT). The intensity of the conditioning regimen correlates with the …

Acute graft versus host disease (aGVHD) remains the second leading cause of death
following allogeneic hematopoietic stem cell transplant (AHSCT). Over the last five years …

Advances in conditioning, graft-versus-host disease (GVHD) prophylaxis and antimicrobial
prophylaxis have improved the safety of allogeneic hematopoietic cell transplantation (HCT) …

Clinical outcomes for patients undergoing allogeneic hematopoietic stem cell
transplantation continue to improve, but chronic graft-versus-host disease (GVHD) remains a …

Background Acute graft-versus-host-disease (GVHD) after non-myeloablative human
leucocyte antigen (HLA)-matched, unrelated donor, allogeneic haemopoietic stem cell …